Kisqali(ribociclib)
Kisqali 200 MG Daily Dose Carton Pack
NO BOXED WARNING
Dosage & Administration
Dosage & Administration
Coverage Restrictions
Find Restrictions and Step Therapies for Kisqali
drug label
Kisqali Prescribing Information
Financial Assistance
Financial Assistance Programs
Kisqali retails for $15,162 per dose without insurance or financial assistance.Depending on your patient's insurance situation and other eligibility criteria, they may be able to get Kisqali for significantly less. Review the program information below to determine what program can offer your patient the most benefits.Copay Card Program$0 Copay
Available for
commercial
Program Details
- $15000 Annual Cap
Forms
Foundation ProgramFirst dose for $0
Available for
uninsured
Eligibility requirements
- Uninsured
- Household annual adjusted gross income <= % FPL.
Forms
patient education
Kisqali Patient Education
To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link
Patient toolkit
people also ask
Kisqali FAQs
Is it safe to take KISQALI during pregnancy?No, KISQALI can cause fetal harm when administered to a pregnant woman based on findings from animal studies and the mechanism of action. The background risk of major birth defects and miscarriage for the indicated population is unknown. Pregnant women should be advised of the potential risk to a fetus.
Can KISQALI be taken while breastfeeding?It is not known if ribociclib, the active ingredient in KISQALI, is present in human milk. Ribociclib and its metabolites readily passed into the milk of lactating rats. Lactating women are advised not to breastfeed while taking KISQALI and for at least 3 weeks after the last dose.
Should females of reproductive potential take any precautions while taking KISQALI?Females of reproductive potential should undergo pregnancy testing prior to starting treatment with KISQALI. Effective contraception methods that result in less than 1% pregnancy rates are recommended during treatment with KISQALI and for at least 3 weeks after the last dose.
Can KISQALI be used in pediatric patients?No, the safety and efficacy of KISQALI in pediatric patients has not been established.
Can KISQALI be used in geriatric patients?No overall differences in safety or effectiveness of KISQALI were observed between geriatric patients (≥65 years old) and younger patients in clinical studies.
Are there any dosage adjustments required for patients with hepatic impairment?No dose adjustment is necessary for patients with mild hepatic impairment (Child-Pugh class A). A reduced starting dose of 400 mg is recommended for patients with moderate (Child-Pugh class B) and severe hepatic impairment (Child-Pugh class C).
Are there any dosage adjustments required for patients with renal impairment?No dose adjustment is necessary for patients with mild or moderate renal impairment. For patients with severe renal impairment (eGFR 15 to < 30 mL/min/1.73 m2), a starting dose of 200 mg is recommended based on a renal impairment study in healthy subjects and non-cancer subjects.
FAQ Data Source